Glycobiology Market Trends

Skyquest Technology's expert advisors have carried out comprehensive research on the glycobiology market to identify the major global and regional market trends and growth opportunities for leading players and new entrants in this market. The analysis is based on in-depth primary and secondary research to understand the major market drivers and restraints shaping the future development and growth of the industry.

Glycobiology Market Dynamics

Glycobiology Market Drivers

Government Investment in Glycomics Research

  • Governments across the globe are spending a lot on glycomics research to enhance health. The government of Australia, for instance, used over USD 10 billion in scientific research innovation between 2017 and 2018, while Ireland used USD 5.6 billion in 2015 on enhancing research activities, with the aim of growing scientific research personnel from 25,000 to 40,000. The investments are driving the growth of the glycobiology market through enhancement and enhanced research capacity. ​

Appearance of Glycans as Disease Diagnosis Biomarkers

  • The discovery of glycans as powerful biomarkers of disease is propelling the glycobiology sector. Cardiovascular disease and cancer have been associated with glycan structural changes. It is known that over 100 types of human congenital disorders of glycosylation have been induced by mutation of glycosyltransferases. Growing awareness is driving glycomics devices and technologies as drug-discovery tools and as diagnostics.

Glycobiology Market Restraints

Very High Research Glycomics Equipment Price

  • The price of glycomics research hardware, such as high-performance liquid chromatography (HPLC) hardware and mass spectrometers, is the most significant barrier to market growth. These instruments range in price from hundreds of thousands to millions of dollars and are therefore out of the reach of small research labs and start-up biotechnology companies. In addition, specialty reagents utilized in glycan analysis contribute to the cost of doing business, preventing extensive adoption of glycomics technologies.

Lack of Standardized Protocols for Glycomic Analysis

  • Absence of standardized techniques and protocols of glycan analysis limits reproducibility and comparability of outcomes among studies. Variation in glycomic analysis protocols makes data interpretation and integration challenging, limiting collaboration and the rapid translation of glycomics research to the clinic.
REPORT OVERVIEW BUY NOW

REQUEST FOR SAMPLE

Want to customize this report? REQUEST FREE CUSTOMIZATION

FAQs

Global Glycobiology Market size was valued at USD 2.0 billion in 2023 and is poised to grow from USD 2.3 billion in 2024 to USD 6.98 billion by 2032, growing at a CAGR of 14.9% during the forecast period (2025-2032).

​ The glycobiology market is characterized by strong competition among the leading companies such as Thermo Fisher Scientific, Agilent Technologies, Merck KGaA, Bruker Corporation, and New England Biolabs. They are all spending a lot of money on research and development to enhance their product portfolios and maintain top position in the market. For instance, Merck KGaA announced investment of over USD 320 million in a new Life Science Research Center in Germany, Darmstadt, to focus on mRNA and antibody production applications, the very essence of glycobiology research. Strategic partnerships and mergers and acquisitions also play important roles in determining market trends. Bruker Corporation's acquisition of IonSense in 2022 was to boost its mass spectrometry capabilities, a major application domain for glycan analysis. Similarly, GlycoNet's collaboration with BridgeBio Pharma in 2021 was to develop drugs for genetic diseases based on glycobiology research. 'Thermo Fisher Scientific (US)', 'New England Biolabs (US)', 'Merck KGaA (Germany)', 'Promega Corporation (US)', 'Waters Corporation (US)', 'Takara Bio Inc, (Japan)', 'Bio-Techne (US)', 'Agilent Technologies (US)', 'Sumitomo Bakelite Co. Ltd. (Japan)', 'Bruker Corporation (US)', 'Shimadzu Corporation (Japan)', 'Danaher Corporation (US)', 'AMS Bio (UK)', 'Ludger Ltd (UK)', 'Z Biotech, LLC (US)', 'Chemily Glycoscience (US)', 'CD BioGlyco (US)', 'GlycoDiag (France)', 'Kode Biotech Limited (New Zealand)', 'Glyxera GmBH (Germany)'

Governments across the globe are spending a lot on glycomics research to enhance health. The government of Australia, for instance, used over USD 10 billion in scientific research innovation between 2017 and 2018, while Ireland used USD 5.6 billion in 2015 on enhancing research activities, with the aim of growing scientific research personnel from 25,000 to 40,000. The investments are driving the growth of the glycobiology market through enhancement and enhanced research capacity. ​

Why is North America a Leader in Glycobiology?

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Feedback From Our Clients

Global Glycobiology Market
Glycobiology Market

Report ID: SQMIG35H2335

[email protected]
USA +1 351-333-4748

BUY NOW GET FREE SAMPLE